Renal artery stenosis Medical Services in China

Renal artery stenosis (RAS) is a narrowing of one or both renal arteries—the major blood vessels supplying oxygenated blood to the kidneys. This condition impairs renal perfusion, triggering activation of the renin-angiotensin-aldosterone system (RAAS), which can lead to secondary hypertension and progressive chronic kidney disease. The two primary pathogenic mechanisms are atherosclerotic RAS—accounting for over 90% of cases in adults over 50—and fibromuscular dysplasia (FMD), a non-inflammatory, structural vascular disorder more common in younger women under 50. Atherosclerotic RAS typically affects the proximal segment of the main renal artery and is strongly associated with systemic atherosclerosis, while FMD often involves the mid-to-distal arterial segments and presents with a characteristic 'string-of-beads' angiographic appearance. Epidemiologically, RAS prevalence rises sharply with age: it affects approximately 5–10% of adults aged 65–75 years and up to 18–42% of those over 75, particularly among patients with coronary or peripheral artery disease. Key risk factors include advanced age, smoking, hypertension, diabetes mellitus, hyperlipidemia, chronic kidney disease, and a history of cardiovascular disease. Notably, RAS is underdiagnosed—many patients remain asymptomatic until significant renal ischemia or refractory hypertension develops. Clinical manifestations may include sudden-onset or worsening hypertension (especially diastolic or resistant to ≥3 antihypertensives), episodic pulmonary edema, unexplained decline in glomerular filtration rate (GFR), flash pulmonary edema, or recurrent congestive heart failure. Quality of life is substantially impacted: patients frequently experience fatigue, anxiety related to uncontrolled blood pressure, medication burden, reduced physical stamina, and fear of dialysis or cardiovascular events. Untreated severe RAS increases risks of accelerated hypertension, ischemic nephropathy, end-stage renal disease, myocardial infarction, and stroke. Early detection via duplex ultrasonography, CTA, MRA, or captopril renography—combined with individualized risk-benefit assessment—is critical. While revascularization (angioplasty ± stenting) was historically pursued aggressively, landmark trials (e.g., CORAL, STAR) demonstrated that optimal medical therapy—including RAAS inhibition (when safe), statins, antiplatelets, and strict BP and metabolic control—remains first-line for most patients. Revascularization is now reserved for select cases: hemodynamically significant stenosis with acute pulmonary edema, rapidly deteriorating renal function, or unilateral RAS with renovascular hypertension unresponsive to maximal medical therapy. Multidisciplinary management involving nephrologists, interventional radiologists, and cardiologists ensures personalized, evidence-based care and improved long-term outcomes.

Renal artery stenosis (RAS) is a narrowing of one or both renal arteries, most commonly caused by atherosclerosis in older adults (>50 years) or fibromuscular dysplasia (FMD) in younger patients, particularly women. It is a significant contributor to secondary hypertension and ischemic nephropathy, potentially leading to chronic kidney disease (CKD), accelerated cardiovascular morbidity, and end-stage renal disease if left untreated. Management requires a multidisciplinary approach coordinated by nephrologists, interventional radiologists, and vascular surgeons, with treatment strategy guided by symptom severity, hemodynamic significance, renal function trajectory, and comorbid burden.

Conservative management remains the cornerstone for asymptomatic or hemodynamically non-significant RAS, especially in patients with stable renal function and well-controlled hypertension. This includes rigorous cardiovascular risk factor modification: smoking cessation, dietary sodium restriction (<2 g/day), weight optimization, regular aerobic exercise (≥150 min/week moderate intensity), and lipid-lowering therapy targeting LDL-C <70 mg/dL (often with high-intensity statins such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily). Blood pressure control is paramount; goal BP is generally <130/80 mmHg per KDIGO and AHA/ACC guidelines. Lifestyle interventions are reinforced with structured patient education on medication adherence, home BP monitoring, and recognition of acute decompensation signs (e.g., rapid creatinine rise, pulmonary edema).

Pharmacotherapy is central to medical management. Dual renin-angiotensin-aldosterone system (RAAS) blockade is contraindicated due to heightened risk of hyperkalemia, acute kidney injury, and hypotension. Instead, monotherapy with an ACE inhibitor (e.g., lisinopril 5–20 mg daily) or angiotensin receptor blocker (ARB; e.g., losartan 50–100 mg daily) is recommended *only after confirming bilateral RAS or unilateral RAS with a solitary functioning kidney is absent*, and only with close monitoring of serum creatinine and potassium within 1–2 weeks of initiation and periodically thereafter. Calcium channel blockers (e.g., amlodipine 5–10 mg daily) and thiazide-like diuretics (e.g., chlorthalidone 12.5–25 mg daily) are preferred first-line antihypertensives in high-risk anatomical scenarios. Beta-blockers may be added for concomitant coronary artery disease or heart failure. Antiplatelet therapy (aspirin 75–100 mg daily) is indicated for all atherosclerotic RAS patients unless contraindicated, given their high atherosclerotic burden.

Surgical and endovascular interventions are reserved for select patients meeting strict criteria: (1) progressive CKD (eGFR decline >3 mL/min/1.73 m²/year) attributable to RAS; (2) recurrent flash pulmonary edema unresponsive to optimal medical therapy; (3) medically refractory hypertension (≥3 agents including a diuretic); or (4) unilateral RAS with renin-mediated hypertension confirmed by renal vein renin sampling (RVRS) or captopril-enhanced renography. Percutaneous transluminal renal angioplasty with stenting (PTRAS) is the most common revascularization procedure. In atherosclerotic RAS, bare-metal or drug-eluting stents are deployed following predilation; technical success exceeds 95% in experienced centers. For FMD, balloon angioplasty alone—without stent placement—is standard, achieving >90% long-term patency. Surgical options—including bypass grafting (e.g., saphenous vein or PTFE to renal artery), endarterectomy, or autotransplantation—are considered when anatomy precludes endovascular access (e.g., ostial lesions with severe aortic calcification, multiple branch vessel involvement) or after failed stenting. While early enthusiasm for routine stenting was tempered by the negative results of the CORAL and STAR trials—which showed no incremental benefit over medical therapy alone for cardiovascular or renal outcomes in broadly selected atherosclerotic RAS—the current consensus favors highly selective revascularization in carefully phenotyped patients with objective evidence of hemodynamic compromise and target-organ damage.

China offers distinct advantages in RAS management, particularly in procedural expertise and integrated care delivery. Major academic hospitals (e.g., Peking University First Hospital, Shanghai Renji Hospital, West China Hospital) perform over 2,000 renal artery interventions annually, with operators trained in advanced intravascular ultrasound (IVUS) and fractional flow reserve (FFR)-renal to objectively assess stenosis significance beyond angiographic appearance. Domestic innovation has led to cost-effective, high-performance drug-coated balloons and bioresorbable scaffolds currently under phase III evaluation in multicenter RCTs. Moreover, China’s national hypertension and CKD registries enable real-time outcome tracking and risk-stratified follow-up protocols. Tele-nephrology platforms facilitate seamless post-procedural monitoring across provincial lines, while standardized discharge bundles—including bilingual (Mandarin–English) medication guides and AI-powered BP/creatinine trend analysis—enhance adherence and early complication detection. Importantly, China’s tiered healthcare system ensures timely referral from primary care clinics to tertiary nephrology centers, minimizing diagnostic delays.

Recovery and long-term surveillance require structured guidance. Following successful revascularization, patients should avoid heavy lifting (>10 kg) and strenuous activity for 7 days post-procedure to prevent access-site complications. Dual antiplatelet therapy (aspirin plus clopidogrel/ticagrelor) is prescribed for 1–3 months post-stent, then aspirin monotherapy indefinitely. Renal function and BP must be monitored at 1, 3, 6, and 12 months post-intervention, with annual duplex ultrasonography to assess stent patency and velocity indices (peak systolic velocity >180 cm/sec suggests restenosis). Patients are advised to maintain strict glycemic control (HbA1c <7.0% if diabetic), avoid NSAIDs and iodinated contrast without hydration protocols, and undergo annual cardiovascular risk assessment (ECG, echocardiogram, carotid IMT). Psychosocial support—including hypertension self-management workshops and peer-led CKD support groups—is increasingly embedded in outpatient nephrology programs across urban centers. Ultimately, optimal RAS outcomes depend not on isolated intervention but on sustained, protocol-driven collaboration between patient, primary care provider, and nephrology specialist—emphasizing prevention, precision diagnostics, and personalized longitudinal care.